[CytoReason in GlobeNewswire] CytoReason to license its IBD disease model to Sanofi in expanded multiyear, multimillion dollar deal

Collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for inflammatory bowel disease (IBD).

Read more here.